Star Therapeutics says it raised $200 million to advance its hematology and immunology pipeline after selling Vega and seeing former subsidiary Electra go public.
Why it matters: The financing effectively resets Star as an early-stage biotech after Vega's sale and Electra's IPO, CEO Adam Rosenthal tells Axios Pro.
